DO HYUN LEE

Biomedical Researcher specializing in Nanomedicine and Drug Delivery Systems (DDS). Currently a Research Scientist at The DABOM Inc., spearheading the development of artificial exosomes (ENPs) using bottom-up assembly techniques. Proven expertise in designing bio-mimetic nanoparticles and validating their therapeutic efficacy through comprehensive in vitro and in vivo studies. Possesses a strong academic background in erythrocyte membrane-derived technologies from Yonsei University.

Microfluidic Mass Production Platform of Artificial Exosomes

• Funding Agency: Korea Technology & Information Promotion Agency for SMEs (TIPA) (Grant No. 2420017389)
• Program: TIPS Program (Tech Incubator Program for Startup)
• Affiliation: The DABOM Inc.
• Period: Sep. 2024 – Aug. 2027
• Total Funding: KRW 416 Million (~$300,000)
• Role: Participating Researcher

Evaluation of Therapeutic Efficacy of Exosome-Like Nanovesicles (ELNVs) Synthesized via Microfluidic Chips

• Funding Agency: Korea Technology & Information Promotion Agency for SMEs (TIPA) (Grant No. 2420005688)
• Program: Startup Growth Technology Development Project (Didimdol)
• Affiliation: The DABOM Inc.
• Period: Aug. 2024 – Jul. 2025
• Total Funding: KRW 80 Million (~$57,000)
• Role: Participating Researcher

Microfluidic Technology-Based Bioprocess Platform for Purification, Concentration, and Analysis of Biocarriers for Next-Generation Drugs

• Funding Agency: Korea Technology & Information Promotion Agency for SMEs (TIPA) (Grant No. 2420024925)
• Program: SME Technology Innovation Development Project (Export-Oriented)
• Affiliation: The DABOM Inc.
• Period: Sep. 2025 – Aug. 2029
• Total Funding: KRW 250 Million (~$180,000)
• Role: Participating Researcher

Development of combinatorial delivery system for PD-1/PD-L1 antagonist and doxorubicin using erythrocyte membrane-derived theranostic nanoparticle

• Funding Agency: National Research Foundation of Korea (NRF) / Ministry of Science and ICT (Grant No. 1711156049)
• Affiliation: Yonsei University
• Period: Jul. 2020 – Fab. 2023
• Total Funding: KRW 137.5 Million (~$100,000)
• Role: Graduate Research Assistant

• Outstanding Poster Presentation Award, The Korean Society For Biomedical Laboratory Sciences, Nov 2022.
• Outstanding Oral Presentation Award, The Korean Society For Biomedical Laboratory Sciences, Nov 2021.
• 2020 Capstone Design Award Grand Prize, Yonsei University, Nov 2020.

• Ha, S.†, Lee, D. H.†, Lee, T.†, Jiang, H.†, Lee, H. J., Seo, S., Yang, J. Y., Park, S., Park, S. G., Shin, J., & Jung, H. I. "Machine learning-driven rational design of exosome-mimetic lipid nanoparticles for cancer therapy." Nano Convergence (Under Revision). (Co-first Author)
• Yang, J. Y., Kim, D. U., Choi, S., Lee, D. H., Lee, H., Kim, M. W., Park, S. J., Jeon, J., Kim, D., Cho, Y., Hyun, K. A., Park, S., & Jung, H. I. "ABCG36-Selected Plant Nanovesicles via Automated Microfluidic Enrichment System (AMESYS) for Anti-Inflammatory Modulation." Sensors and Actuators B: Chemical (Submitted, Manuscript No. SNB-D-25-10322). (Co-author)
• Kim, J.†, Lee, D. H.†, Seo, H.†, Lee, H. J., Kim, G., Nie, C., Hong, Y., Yoon, Y. J., Lim, J. Y., Park, S. J., Yang, J. Y., Choi, S., Park, S., & Jung, H. I. "Microfluidic Generation of Exosome-Mimetic Nanoparticles for Scalable Production and Enhanced Therapeutic Efficacy." Small 21 (2025): 2506162. (Co-first Author)
• Choi, K. C.†, Lee, D. H.†, Lee, J. W., & Park, Y. S. "Advancements in Cancer Immunotherapy: The Evolution and Future of mRNA and DNA Vaccine Technologies." Biomedical Science Letters 31(1) (Mar. 2025): 1–11. (Co-first Author)
• Choi, K. C., Jeong, H. Y., Lee, D. H., Lee, J. W., Hong, J. E., Baek, J. E., & Park, Y. S. "Innovative Cancer Immunotherapy with MAGE-A3 mRNA Cancer Vaccines." Cancers 16(19) (Oct. 2024): 3428. (Co-author)
• Choi, M. J., Kang, S. J., Lee, Y. K., Choi, K. C., Lee, D. H., Jeong, H. Y., Kim, M. W., Kim, K. S., & Park, Y. S. "Novel Lipid Nanocomplex Co-Carrying Bcl2 siRNA and Quantum Dots for EGF Receptor-Targeted Anti-Cancer Theranosis." International Journal of Molecular Sciences 25(11) (Jun. 2024): 6246. (Co-author)
• Choi, K. C.†, Lee, D. H.†, Lee, J. W., Lee, J. S., Lee, Y. K., Choi, M. J., Jeong, H. Y., Kim, M. W., Lee, C. G., & Park, Y. S. "Novel Lipid Nanoparticles Stable and Efficient for mRNA Transfection to Antigen-Presenting Cells." International Journal of Molecular Sciences 25(3) (Jan. 2024): 1388. (Co-first Author)
• Choi, M. J., Lee, Y. K., Choi, K. C., Lee, D. H., Jeong, H. Y., Kang, S. J., Kim, M. W., You, Y. M., Im, C. S., Lee, T. S., & Park, Y. S. "Tumor-Targeted Erythrocyte Membrane Nanoparticles for Theranostics of Triple-Negative Breast Cancer." Pharmaceutics 15(1) (Jan. 2023): 350. (Co-author)
• Choi, M. J., Choi, K. C., Lee, D. H., Jeong, H. Y., Kang, S. J., Kim, M. W., Jeong, I. H., You, Y. M., Lee, J. S., Lee, Y. K., Im, C. S., & Park, Y. S. "EGF Receptor-Targeting Cancer Therapy Using CD47-Engineered Cell-Derived Nanoplatforms." Nanotechnology, Science and Applications 15 (Jul. 2022): 17–31. (Co-author)